Want to see CYRX full AI Analyst Report?
Top Page
CryoPort
(NASDAQ:CYRX)
Select Model
Select Model
Rating:63Neutral
Price Target:
$17.50
▲(90.01% Upside)
Action:Reiterated
Date:06/10/26
Overall score reflects weak underlying cash generation and still-negative operating profitability as the main constraint, partially offset by strong technical uptrend and a constructive earnings update (raised revenue guidance and improving adjusted EBITDA trajectory). Valuation is supportive (P/E ~10) but is tempered by the cash-flow and profitability profile.
Positive Factors
Clinical & Commercial Scale
A large, growing base of 766 supported clinical trials and 21 commercial therapies creates durable, recurring demand. As trials progress to later phases and approvals, Cryoport benefits from stickier commercial conversions, higher per-shipment values, and predictable volume growth over multiple years.
Negative Factors
Weak Cash Generation
Material negative free cash flow and roughly breakeven operating cash flow imply the business is not consistently self-funding. This reduces financial flexibility, increases reliance on external financing for capex/expansions, and heightens risk if revenue or margins soften during multi-quarter ramps.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical & Commercial Scale
A large, growing base of 766 supported clinical trials and 21 commercial therapies creates durable, recurring demand. As trials progress to later phases and approvals, Cryoport benefits from stickier commercial conversions, higher per-shipment values, and predictable volume growth over multiple years.
Read all positive factors
CryoPort Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down sales across regions to reveal geographic strengths and concentration risks, indicating where the company is expanding, which markets drive growth, and where regulatory or economic changes could affect future revenue.
Breaks down sales across regions to reveal geographic strengths and concentration risks, indicating where the company is expanding, which markets drive growth, and where regulatory or economic changes could affect future revenue.
Data provided by:
The Fly
The FlyCryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$832.14M
Dividend YieldN/A
Average Volume (3M)690.07K
Price to Earnings (P/E)11.5
Beta (1Y)1.32
Revenue Growth-14.85%
EPS Growth62.35%
CountryUS
Employees738
SectorIndustrials
Sector Strength72
IndustryIntegrated Freight & Logistics
Share Statistics
EPS (TTM)1.43
Shares Outstanding50,402,313
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-17.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.83Price Target Upside61.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$194.39M
CryoPort Business Overview & Revenue Model
Company Description
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central t...
How the Company Makes Money
Cryoport primarily makes money by selling specialized temperature-controlled logistics and related supply chain services to biopharmaceutical and life sciences customers that need compliant, validated transport and handling for sensitive biologica...
CryoPort Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and financial picture: strong 16% revenue growth, double-digit expansion across services and products, record clinical trial support, product innovation (Fusion 800), and a $2.2M improvement in adjusted EBITDA. Management raised full-year revenue guidance and expects positive adjusted EBITDA in H2 2026. Key near-term cautions include a conservative guide raise despite a beat, the company not yet at positive adjusted EBITDA, product-margin mix variability, and multi-quarter ramps for IntegraCell and new facilities that limit 2026 contribution. Overall the positives (top-line growth, pipeline depth, milestones, margin improvement initiatives, and operational expansions) materially outweigh the identified lowlights.Positive Updates
Top-Line Growth
Revenue of $47.8 million in Q1 2026, up 16% year over year, representing a strong start to the year and prompting an upward revision to full-year revenue guidance of $192 million to $196 million.
Negative Updates
Cautious Guiding Despite Beat
Although Q1 beat consensus by $3 million, management raised full-year guidance only modestly ($1 million), citing macroeconomic uncertainty and taking a conservative stance early in the year.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Growth
Revenue of $47.8 million in Q1 2026, up 16% year over year, representing a strong start to the year and prompting an upward revision to full-year revenue guidance of $192 million to $196 million.
Read all positive updates
Company Guidance
Management raised full‑year 2026 revenue guidance to $192–$196 million (continuing operations) after a strong Q1 start with revenue of $47.8 million, up 16% year‑over‑year; Q1 commercial cell & gene therapy revenue was $9.1M (up 26% YoY), clinical trial revenue was $12.9M (up 18% YoY), Life Sciences Services revenue rose 18% with biostorage/bioservices up 21%, and Life Sciences Products grew 15%; the company now supports 766 global clinical trials (net +55 YoY) including 91 Phase III programs, supports 21 commercial therapies with up to eight potential new approvals this year (five with PDUFA dates), and reported a $2.2M year‑over‑year improvement in adjusted EBITDA from continuing operations (Q1 adjusted EBITDA ~‑$0.6M), reiterating an expectation to reach positive adjusted EBITDA in the second half of 2026 and noting they will reassess guidance quarterly.CryoPort Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
68
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 182.94M | 176.18M | 233.25M | 237.28M | 222.61M | 78.70M |
| Gross Profit | 86.33M | 83.05M | 99.33M | 103.87M | 96.58M | 36.33M |
| EBITDA | -6.31M | -2.10M | -66.36M | -6.19M | -248.91M | -20.31M |
| Net Income | 77.16M | 78.30M | -99.59M | -37.33M | -275.53M | -32.69M |
Balance Sheet | ||||||
| Total Assets | 763.61M | 764.99M | 703.49M | 957.74M | 1.04B | 552.40M |
| Cash, Cash Equivalents and Short-Term Investments | 403.63M | 411.21M | 261.75M | 456.75M | 523.32M | 93.32M |
| Total Debt | 230.49M | 230.72M | 250.70M | 416.00M | 435.91M | 130.92M |
| Total Liabilities | 268.62M | 262.35M | 301.59M | 468.72M | 482.91M | 169.71M |
| Stockholders Equity | 494.99M | 502.64M | 401.90M | 489.02M | 555.84M | 382.70M |
Cash Flow | ||||||
| Free Cash Flow | -24.36M | -28.09M | -33.58M | -45.66M | -26.05M | -24.54M |
| Operating Cash Flow | -503.00K | -8.58M | -16.32M | -757.00K | -1.85M | -14.87M |
| Investing Cash Flow | 263.12M | 250.32M | 176.81M | 36.05M | -59.68M | -382.31M |
| Financing Cash Flow | -20.80M | -21.07M | -161.53M | -23.80M | -39.17M | 385.58M |
CryoPort Technical Analysis
Positive
9.21
Price Trends
14.90
Positive
11.98
Positive
10.75
Positive
Market Momentum
0.47
Negative
62.83
Neutral
84.62
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 9.21 is below the 20-day moving average (MA) of 15.70, below the 50-day MA of 14.90, and below the 200-day MA of 10.75, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 62.83 is Neutral, neither overbought nor oversold. The STOCH value of 84.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.
CryoPort Risk Analysis
CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CryoPort Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $27.48B | 41.39 | 17.30% | 0.89% | 5.28% | ― | |
68 Neutral | $74.68B | 17.05 | 15.76% | 1.94% | 7.73% | ― | |
68 Neutral | $18.16B | 14.18 | 14.20% | 2.98% | 15.87% | 1.18% | |
64 Neutral | $25.25B | 72.89 | 19.04% | ― | 3.63% | -11.81% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | $832.14M | 11.55 | 16.16% | ― | -14.85% | 62.35% | |
56 Neutral | $6.22B | 46.40 | 4.46% | ― | 10.38% | 84.52% |
* Industrials Sector Average
CYRX
CryoPort
16.51
9.80
146.05%
XPO
XPO
215.02
86.58
67.41%
FDX
FedEx
312.98
134.68
75.54%
JBHT
JB Hunt
291.41
145.22
99.34%
ZTO
ZTO Express
23.92
5.57
30.33%
GXO
GXO Logistics
54.05
3.76
7.48%
CryoPort Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Cryoport Shareholders Back Board, Auditor and Equity Plan
Positive
Jun 9, 2026
At its annual meeting on June 5, 2026, Cryoport, Inc. shareholders elected six directors, including Linda Baddour and CEO Jerrell W. Shelton, to serve until the 2027 meeting, reaffirming the company’s current board leadership. Investors also...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.